46 Remember – when you contact a Member, please tell them you found them in the 2018 LSQ Member Directory Section 3: Life Sciences Queensland Ltd Sub Sectors
The International Council for Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH) has announced the TGA has ICH observer status.
The TGA has joined other ICH observers; the Southern African
Development Community (SADC), the Gulf Cooperation Council
(GCC), the Agência Nacional de Vigilância Sanitária (ANVISA)
of Brazil, the Pan American Network for Drug Regulatory
Harmonization (PANDRH), and the Asia-Pacific Economic
3.4.3 Complementary Medicines and
Complementary medicines (CM) can be defined as “a group of
diagnostic and therapeutic disciplines that are used together
with conventional medicine,” which aim to prevent, treat or
manage illness. Such products and therapies include vitamins,
minerals, herbal remedies, aromatherapy, Chinese medicine
and homoeopathy. It is estimated that two in three Australians
use CM each year and 42 per cent do so to prevent or manage
chronic conditions identified as national health priorities - this is
one of the highest consumption rates per capita in developed
Australia has significant strengths in CM research and the
sector is a growing contributor to the country's economy.
Industry revenue is currently AU$3.5 billion and is expected to
grow to AU$4.6 billion in 2017-2018, with industry employment
expected to rise to 45,000.
Queensland is a key segment within Australia's CM industry,
which receives State Government support and boasts many
advantages including a competitive manufacturing environment.
The State houses more than 400 CM and nutrition companies
and employs approximately 10,000 Queenslanders.
To continue boosting CM industry growth, organisations such
as the National Institute of Complementary Medicine (NICM)
provide a platform for a coordinated national approach to building
complementary medicine research capacity and addressing
issues around CM, including bridging the gap between available
evidence and the health potential and use of CM and managing
and establishing sources of reliable and accurate information
about safety, efficacy and value of CM. Preliminary research
indicates that the field can make a significant, cost-effective
contribution to the country's healthcare system, particularly in
the areas of chronic disease management and preventative,
aged and palliative care.
Australia follows a risk-based system for the regulation of
CM, with those registered being evaluated for quality, safety
and efficacy by the Complementary and Over-the-counter
Medicines Branch Office of Complementary and Over-the-counter
Medicines Branch of the TGA. However, it should be
noted that listed complementary medicines require the sponsor
to hold evidence to support drug efficacy. Clinical trials are
essential in establishing efficacy.
For more information, visit the TGA’s website at www.tga.gov.au,
or contact LSQ to be directed to the appropriate LSQ Members
Queensland's Needle-less patch: novel vaccine delivery
technology - Case Study
The NanopatchTM was developed by Professor Mark Kendall and
his research group at the Australian Institute of Bioengineering &
Nanotechnology (AIBN) at UQ. The technology is being developed
and commercialised by Vaxxas, a venture capital backed start-up
founded by Professor Kendall, with the approach to improve
the performance of vaccines, with initial applications targeting
infectious disease and oncology.
The initial investments into Vaxxas have been made by an array
of international investors, including One Ventures and Brandon
Capital. More recently, Vaxxas has raised $AU25 million through
a funding round led by One Ventures, which will be used to
advance a series of clinical programs and develop a pipeline of
new Nanopatch-based vaccine products.
Other collaborations that are working towards using the
NanopatchTM to deliver vaccines include Vaxxas and the World
Health Organisation (WHO). In late 2014, Vaxxas announced the
initiation of a research project funded by WHO, to evaluate the
NanopatchTM as a platform for the delivery of polio vaccine.
Following the successful completion of this research, and all
subsequent necessary clinical development and regulatory
approvals, Vaxxas would have the opportunity to supply
Nanopatches to help secure a lasting polio-free world.
Polio was one of the most dreaded childhood diseases of the 20th
century, resulting in limb disfigurement and irreversible paralysis in
tens of millions of cases.
Highlighting the novel approach of the NanopatchTM, CEO of
Vaxxas David L. Hoey said "The Nanopatch doesn't need to be
kept refrigerated to maintain its efficacy - a tremendously important
factor for the transportation and application of polio vaccine in the
remote regions of the world where eradication efforts are most
"The research we are undertaking with WHO's support aims to
provide better vaccine solutions to reach all children anywhere
with this life-saving health intervention."
The Nanopatch applicator and a large version of the patch (source: